Hidden immune cells in lymph nodes may resist MS drug, new study investigates
NCT ID NCT06495593
First seen Apr 05, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study looks at whether the MS drug ocrelizumab effectively removes B cells from lymph nodes, not just from the blood. Researchers will analyze lymph node samples from 5 people with relapsing-remitting MS who are starting ocrelizumab. The goal is to understand why some immune cells may survive treatment and how that affects long-term disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.